[go: up one dir, main page]

PE20090982A1 - Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) - Google Patents

Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)

Info

Publication number
PE20090982A1
PE20090982A1 PE2008001884A PE2008001884A PE20090982A1 PE 20090982 A1 PE20090982 A1 PE 20090982A1 PE 2008001884 A PE2008001884 A PE 2008001884A PE 2008001884 A PE2008001884 A PE 2008001884A PE 20090982 A1 PE20090982 A1 PE 20090982A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
cetp
cholesteryl
inhibitors
Prior art date
Application number
PE2008001884A
Other languages
English (en)
Inventor
Muneto Mogi
Ken Yamada
Kayo Yasoshima
Toshio Kawanami
Ichiro Umemura
Yuki Iwaki
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40343337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090982(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20090982A1 publication Critical patent/PE20090982A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIPERIDINA DE FORMULA (I) DONDE R1 ES CICLOALQUILO, ARILO, ALQUILO, ENTRE OTROS; R2 ES ALQUILO, CICLOALQUILO, ALCOXILO, ENTRE OTROS; R3 ES HOC(O)-R9-C(O)- O HOC(O)-R9-O-C(O)-, EN DONDE R9 ES ALQUILO, ALQUIL-CICLOALQUIL, ARILO, ENTRE OTROS; R4 Y R5 SON CADA UNO H, ALQUILO, ALCOXILO, CICLOALQUILO, ARILO, ENTRE OTROS; R6 Y R7 SON CADA UNO H, ALQUILO, HALO-ALQUILO, HALOGENO, CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-CARBAMOIL-BUTIL-ESTER DEL ACIDO CIS-4-{[3,5-BIS-(TRIFLUORO-METIL)-BENCIL]-[5-(1-METIL-1H-PIRAZOL-4-IL)-PIRIMIDIN-2-IL]-AMINO}-2,6-DIETIL-PIPERIDIN-1-CARBOXILICO, TERBUTIL-ESTER DEL ACIDO CIS-2-BENCIL-4-[(3,5-BIS-(TRIFLUORO-METIL)-BENCIL)-(5-MORFOLIN-4-IL-PIRIMIDIN-2-IL)-AMINO]-6-ETIL-PIPERIDIN-1-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA DE TRANSFERENCIA DE COLESTERIL-ESTER (CETP) SIENDO UTILES EN EL TRATAMIENTO DE HIPERLIPIDEMIA, ATEROSCLEROSIS, ENFERMEDAD CARDIACA CORONARIA
PE2008001884A 2007-11-05 2008-11-03 Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) PE20090982A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98545607P 2007-11-05 2007-11-05

Publications (1)

Publication Number Publication Date
PE20090982A1 true PE20090982A1 (es) 2009-08-13

Family

ID=40343337

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001884A PE20090982A1 (es) 2007-11-05 2008-11-03 Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)

Country Status (24)

Country Link
US (3) US8193349B2 (es)
EP (2) EP2463282B1 (es)
JP (1) JP5555635B2 (es)
KR (1) KR101564793B1 (es)
CN (1) CN101910150B (es)
AR (1) AR069165A1 (es)
AT (1) ATE550333T1 (es)
AU (1) AU2008324243B2 (es)
BR (1) BRPI0819223A2 (es)
CA (1) CA2704633C (es)
CL (1) CL2008003284A1 (es)
CY (1) CY1112706T1 (es)
DK (1) DK2207775T3 (es)
EA (1) EA022912B1 (es)
ES (2) ES2381518T3 (es)
HR (1) HRP20120476T1 (es)
JO (1) JO2732B1 (es)
MX (1) MX2010004929A (es)
PE (1) PE20090982A1 (es)
PL (2) PL2207775T3 (es)
PT (2) PT2207775E (es)
SI (1) SI2207775T1 (es)
TW (1) TWI426910B (es)
WO (1) WO2009059943A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100093103A (ko) 2007-12-03 2010-08-24 노파르티스 아게 고지혈증 또는 동맥경화증과 같은 질환의 치료에 유용한 ｃετρ 억제제로서의 1,2-이치환된 4-벤질아미노-피롤리딘 유도체
NZ597059A (en) 2009-06-17 2014-01-31 Vertex Pharma Inhibitors of influenza viruses replication
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
DK2646444T3 (da) 2010-12-03 2016-06-27 Epizyme Inc Substituerede purin- og 7-deazapurinforbindelser som modulatorer af epigenetiske enzymer
EP2668507B1 (en) 2011-01-26 2017-08-23 INSERM - Institut National de la Santé et de la Recherche Médicale Method for assessing a subject's risk of having a cardiovascular disease.
PL3141548T3 (pl) * 2011-07-05 2020-09-07 Vertex Pharmaceuticals Incorporated Sposoby i związki pośrednie do wytwarzania azaindoli
PT2729142T (pt) * 2011-07-08 2018-10-01 Novartis Ag Método de tratamento de aterosclerose em sujeitos com nível elevado de triglicéridos
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2013074557A1 (en) 2011-11-14 2013-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
BR112014029295B1 (pt) 2012-05-25 2021-04-27 Nutech Ventures Ciclobutenos e ciclobutanos anfifílicos e composição farmacêutica que os compreende
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
US9266925B2 (en) 2013-07-25 2016-02-23 Novartis Ag Cyclic polypeptides for the treatment of heart failure
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
WO2015073481A1 (en) 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
CN104788482B (zh) * 2015-01-23 2016-09-14 沧州普瑞东方科技有限公司 一种制备2-氨基嘧啶-5-硼酸频那醇酯的方法
CN107406490A (zh) 2015-01-23 2017-11-28 诺华股份有限公司 具有改善的半衰期的合成apelin脂肪酸缀合物
MX2017013267A (es) 2015-04-15 2018-08-15 Regeneron Pharma Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8).
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
IL321873A (en) 2018-03-01 2025-08-01 Regeneron Pharma Methods for altering body composition

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
TW313568B (es) 1994-12-20 1997-08-21 Hoffmann La Roche
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
AU6160899A (en) 1998-09-25 2000-04-17 Monsanto Company (r)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
US6476057B1 (en) 1999-09-23 2002-11-05 G.D. Searle & Co. Use of substituted N, N-disubstituted cycloalkyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
JP4954426B2 (ja) 2000-06-16 2012-06-13 キュリス，インコーポレイテッド 血管形成調節組成物及び利用
GB0021885D0 (en) 2000-09-06 2000-10-18 Fujisawa Pharmaceutical Co New use
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
PT1534340E (pt) 2002-09-06 2012-03-13 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
TW200408393A (en) 2002-10-03 2004-06-01 Ono Pharmaceutical Co Antagonist of lysophosphatidine acid receptor
WO2004101529A1 (ja) 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
EP1670765A2 (en) * 2003-09-30 2006-06-21 Pfizer Products Inc. Cetp inhibitors and metabolites thereof
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
ATE402180T1 (de) 2004-03-26 2008-08-15 Lilly Co Eli Verbindungen zur behandlung von dyslipidemie
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
US20060270675A1 (en) 2005-03-10 2006-11-30 Groneberg Robert D Inhibitors of cholesterol ester transfer protein
WO2006098394A1 (ja) 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
JP4258499B2 (ja) * 2005-07-25 2009-04-30 ヤマハ株式会社 吹奏電子楽器の音源制御装置とプログラム
CA2637057A1 (en) 2006-01-13 2007-07-26 Schering Corporation Diaryl piperidines as cb1 modulators
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
WO2007107843A1 (en) 2006-03-22 2007-09-27 Pfizer Products Inc. Methods of treatment with cetp inhibitors
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
KR101149274B1 (ko) 2006-07-20 2012-05-29 노파르티스 아게 Ｃετρ 억제제로서의 아미노-피페리딘 유도체
JP4846769B2 (ja) 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
KR20100093103A (ko) 2007-12-03 2010-08-24 노파르티스 아게 고지혈증 또는 동맥경화증과 같은 질환의 치료에 유용한 ｃετρ 억제제로서의 1,2-이치환된 4-벤질아미노-피롤리딘 유도체
CN101883764B (zh) 2007-12-07 2013-11-13 诺华股份有限公司 吡唑衍生物及其作为细胞周期蛋白依赖性激酶抑制剂的用途

Also Published As

Publication number Publication date
ES2434417T3 (es) 2013-12-16
PT2207775E (pt) 2012-05-11
KR20100094986A (ko) 2010-08-27
AR069165A1 (es) 2010-01-06
HRP20120476T1 (hr) 2012-06-30
BRPI0819223A2 (pt) 2020-08-18
MX2010004929A (es) 2010-05-27
JO2732B1 (en) 2013-09-15
EP2463282A1 (en) 2012-06-13
PT2463282E (pt) 2013-11-11
CA2704633C (en) 2015-10-20
TW200924779A (en) 2009-06-16
TWI426910B (zh) 2014-02-21
AU2008324243B2 (en) 2012-03-08
US20120264773A1 (en) 2012-10-18
ES2381518T3 (es) 2012-05-29
US8420641B2 (en) 2013-04-16
US20090118287A1 (en) 2009-05-07
EP2207775A1 (en) 2010-07-21
JP2011503026A (ja) 2011-01-27
WO2009059943A1 (en) 2009-05-14
JP5555635B2 (ja) 2014-07-23
KR101564793B1 (ko) 2015-10-30
CY1112706T1 (el) 2016-02-10
SI2207775T1 (sl) 2012-05-31
DK2207775T3 (da) 2012-06-18
AU2008324243A1 (en) 2009-05-14
CL2008003284A1 (es) 2009-05-15
EP2207775B1 (en) 2012-03-21
US8193349B2 (en) 2012-06-05
CN101910150B (zh) 2013-09-18
HK1168096A1 (en) 2012-12-21
EA201000750A1 (ru) 2010-12-30
CA2704633A1 (en) 2009-05-14
ATE550333T1 (de) 2012-04-15
CN101910150A (zh) 2010-12-08
EA022912B1 (ru) 2016-03-31
PL2463282T3 (pl) 2014-01-31
PL2207775T3 (pl) 2012-08-31
EP2463282B1 (en) 2013-08-07
US8440682B2 (en) 2013-05-14
US20120208816A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
PE20090982A1 (es) Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
PE20120632A1 (es) Inhibidores de bace
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20130242A1 (es) Derivados de isoxazolo-piridina
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20070585A1 (es) Derivados de sulfonamida como activadores de glucoquinasa
PE20080772A1 (es) Nuevos derivados de bipiridina sustituidos y su uso
PE20141375A1 (es) Activadores de glucoquinasa
PE20110404A1 (es) Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de la orexina
AR051485A1 (es) Pirazolo pirimidinas 1,4-sustituidas como inhibidores de quinasa
PE20121158A1 (es) Derivados de feniletinilo como moduladores alostericos positivos (map)
PE20110419A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
PE20110409A1 (es) Compuestos heterociclicos antiviricos
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20141529A1 (es) Derivados de biciclo [3,2,1] octilamida y sus usos
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
PE20070528A1 (es) Compuestos heterociclicos como ligandos del receptor vaniloide del subtipo 1
PE20080345A1 (es) Derivados de piperazina como agonistas del receptor de gpr38

Legal Events

Date Code Title Description
FG Grant, registration